LY-510929, a peroxisome proliferator-activated receptor (PPAR) agonist, is used potentially for the treatment of hyperlipidaemia, metabolic disorders and type 2 diabetes.
Lubabegron, also known as LY591281; LY488756 fumarate, is a veterinary drug used to reduce ammonia emissions from animals and their waste. Ammonia emissions are a concern in agricultural production because of detrimental effects on the environment, human health, and animal health. Lubabegron was approved by the U.S. Food and Drug Administration in 2018 for use in feedlot cattle. Lubabegron is a beta-adrenergic receptor agonist that has the effect of increasing the breakdown of fats and increasing energy expenditure in cells.
LY541850 is a selective orthosteric mGlu2 agonist and mGlu3 antagonist with IC50 values of 0.161 μM and 0.038 μM, respectively.LY 541850 is claimed from human ionotropic and metabotropic glutamate (mGlu) receptors expressed in non-neuronal cells.
LY503430 is a AMPA receptor potentiator with oral activity. LY503430 has both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP.
PNU-EDA-Gly5 is a DNA topoisomerase I inhibitor-based oligo-glycine linker-payload used for the synthesis of antibody-drug conjugates (ADCs). It consists of the DNA topoisomerase I inhibitor PNU-159682 and the linker EDA-Gly5.